Ocugen IncNASDAQ:OCGN
- LAST PRICE1.4250
- TODAY'S CHANGE (%)0.0050 (0.3521%)
- Bid / Lots1.4200/ 43
- Ask / Lots1.4300/ 89
- Open / Previous Close1.4400 / 1.4200
- Day Range
- 52 Week Range
- Volume1,771,705
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OCGN |
|---|---|---|
| 09:32 ET | 221248 | 1.4709 |
| 09:34 ET | 105335 | 1.47 |
| 09:36 ET | 28786 | 1.4869 |
| 09:38 ET | 58457 | 1.4849 |
| 09:39 ET | 32723 | 1.485 |
| 09:41 ET | 39675 | 1.485 |
| 09:43 ET | 151486 | 1.445 |
| 09:45 ET | 64769 | 1.47 |
| 09:48 ET | 31302 | 1.46 |
| 09:50 ET | 30657 | 1.4607 |
| 09:52 ET | 11093 | 1.46 |
| 09:54 ET | 49188 | 1.455 |
| 09:56 ET | 5945 | 1.455 |
| 09:57 ET | 58736 | 1.4565 |
| 09:59 ET | 17383 | 1.455 |
| 10:01 ET | 5998 | 1.44 |
| 10:03 ET | 38632 | 1.4521 |
| 10:06 ET | 24213 | 1.4301 |
| 10:08 ET | 12917 | 1.425 |
| 10:10 ET | 6102 | 1.425 |
| 10:12 ET | 32688 | 1.425 |
| 10:14 ET | 32118 | 1.425 |
| 10:15 ET | 25272 | 1.425 |
| 10:17 ET | 6549 | 1.425 |
| 10:19 ET | 54757 | 1.445 |
| 10:21 ET | 28583 | 1.445 |
| 10:24 ET | 2500 | 1.445 |
| 10:26 ET | 30928 | 1.445 |
| 10:28 ET | 7793 | 1.445 |
| 10:30 ET | 26868 | 1.445 |
| 10:32 ET | 5207 | 1.445 |
| 10:33 ET | 8729 | 1.445 |
| 10:35 ET | 19324 | 1.445 |
| 10:37 ET | 46389 | 1.4542 |
| 10:39 ET | 21921 | 1.45 |
| 10:42 ET | 7636 | 1.45 |
| 10:44 ET | 25411 | 1.448 |
| 10:46 ET | 31475 | 1.43 |
| 10:48 ET | 23499 | 1.425 |
| 10:50 ET | 66217 | 1.415 |
| 10:51 ET | 23871 | 1.415 |
| 10:53 ET | 6566 | 1.415 |
| 10:55 ET | 6994 | 1.4152 |
| 10:57 ET | 7483 | 1.42 |
| 11:00 ET | 16285 | 1.42 |
| 11:02 ET | 5400 | 1.41 |
| 11:04 ET | 6943 | 1.415 |
| 11:06 ET | 103800 | 1.425 |
| 11:08 ET | 28099 | 1.425 |
Jun 12, 2024
Jun 10, 2024
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen, from 12:18PM ET on Monday Jun 10, 2024 by Dow Jones
12:18PM ET on Monday Jun 10, 2024 by Dow JonesDEADLINE ALERT for SOND, OCGN, VFS, and QDEL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders, from 12:07PM ET on Monday Jun 10, 2024 by Dow Jones
12:07PM ET on Monday Jun 10, 2024 by Dow JonesOCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, from 12:01PM ET on Monday Jun 10, 2024 by Dow Jones
12:01PM ET on Monday Jun 10, 2024 by Dow JonesOCGN DEADLINE TODAY: TOP RANKED ROSEN LAW FIRM Encourages Ocugen, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm -- OCGN, from 11:46AM ET on Monday Jun 10, 2024 by Dow Jones
11:46AM ET on Monday Jun 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ocugen Inc | 365.4M | -6.1x | --- |
Aura Biosciences Inc | 363.2M | -3.9x | --- |
Korro Bio Inc | 385.8M | -0.9x | --- |
Black Diamond Therapeutics Inc | 335.8M | -3.3x | --- |
enGene Holdings Inc | 396.9M | -2.0x | --- |
XOMA Corp | 294.2M | -6.5x | --- |
Company Information
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.
Contact Information
- Headquarters
- 11 GREAT VALLEY PARKWAYMALVERN, PA, United States 19355
- Phone
- 484-328-4701
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer
- Shankar Musunuri
- Controller
- Michael Breininger
- Chief Scientific Officer, Executive Officer, Head of Research and Development
- Arun Upadhyay
- Chief Medical Officer
- Huma Qamar
- Independent Director
- Kirsten Castillo
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $365.4M |
|---|---|
Revenue (TTM) | $7.1M |
Shares Outstanding | 257.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 3.67 |
EPS | $-0.23 |
Book Value | $0.16 |
P/E Ratio | -6.1x |
Price/Sales (TTM) | 51.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -851.01% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
